TCM
EW icon

Twin Capital Management’s Edwards Lifesciences EW Stock Holding History

Twin Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$680K Sell
8,486
-141
-2% -$11.6K 0.09% 216
2025
Q4 		$735K Buy
8,627
+29
+0.3% +$2.38K 0.09% 197
2025
Q3 		$669K Sell
8,598
-312
-4% -$24.4K 0.08% 206
2025
Q2 		$697K Sell
8,910
-101
-1% -$7.53K 0.07% 204
2025
Q1 		$653K Buy
9,011
+62
+0.7% +$4.44K 0.08% 208
2024
Q4 		$662K Sell
8,949
-121
-1% -$8.47K 0.07% 214
2024
Q3 		$599K Sell
9,070
-362
-4% -$26.3K 0.07% 226
2024
Q2 		$871K Sell
9,432
-192
-2% -$17K 0.1% 185
2024
Q1 		$920K Sell
9,624
-75
-0.8% -$6.3K 0.11% 183
2023
Q4 		$740K Buy
9,699
+2,532
+35% +$176K 0.1% 196
2023
Q3 		$497K Sell
7,167
-729
-9% -$58.6K 0.07% 216
2023
Q2 		$745K Sell
7,896
-181
-2% -$15.7K 0.1% 196
2023
Q1 		$668K Sell
8,077
-359
-4% -$28.2K 0.09% 210
2022
Q4 		$629K Sell
8,436
-26
-0.3% -$2K 0.08% 221
2022
Q3 		$699K Buy
8,462
+500
+6% +$48.1K 0.09% 213
2022
Q2 		$757K Sell
7,962
-100
-1% -$10.4K 0.1% 209
2022
Q1 		$949K Hold
8,062
– – 0.1% 205
2021
Q4 		$1.04M Sell
8,062
-604
-7% -$70.5K 0.1% 194
2021
Q3 		$981K Buy
8,666
+80
+0.9% +$9.13K 0.1% 198
2021
Q2 		$889K Buy
8,586
+2,624
+44% +$247K 0.08% 219
2021
Q1 		$499K Sell
5,962
-4,070
-41% -$344K 0.05% 267
2020
Q4 		$915K Sell
10,032
-359
-3% -$29.8K 0.08% 219
2020
Q3 		$829K Sell
10,391
-305
-3% -$23.8K 0.08% 223
2020
Q2 		$739K Sell
10,696
-4,445
-29% -$316K 0.07% 219
2020
Q1 		$952K Buy
15,141
+270
+2% +$19.5K 0.1% 193
2019
Q4 		$1.16M Sell
14,871
-360
-2% -$28.1K 0.1% 206
2019
Q3 		$1.12M Sell
15,231
-930
-6% -$65.3K 0.08% 206
2019
Q2 		$995K Sell
16,161
-46,779
-74% -$2.83M 0.07% 209
2019
Q1 		$4.01M Sell
62,940
-150
-0.2% -$8.56K 0.2% 153
2018
Q4 		$3.22M Hold
63,090
– – 0.18% 155
2018
Q3 		$3.66M Buy
+63,090
New +$3.09M 0.17% 159
2017
Q4 		– Sell
-150,180
Closed -$5.47M – 329
2017
Q3 		$5.47M Buy
150,180
+24,900
+20% +$950K 0.29% 108
2017
Q2 		$4.94M Buy
125,280
+9,960
+9% +$364K 0.29% 109
2017
Q1 		$3.62M Sell
115,320
-82,410
-42% -$2.58M 0.22% 142
2016
Q4 		$6.18M Buy
197,730
+8,040
+4% +$261K 0.4% 77
2016
Q3 		$7.62M Buy
189,690
+16,770
+10% +$632K 0.51% 54
2016
Q2 		$5.75M Sell
172,920
-15,480
-8% -$530K 0.43% 65
2016
Q1 		$5.54M Buy
188,400
+13,740
+8% +$379K 0.43% 65
2015
Q4 		$4.6M Buy
174,660
+4,620
+3% +$120K 0.38% 77
2015
Q3 		$4.03M Buy
170,040
+3,120
+2% +$75.3K 0.38% 78
2015
Q2 		$3.96M Buy
166,920
+6,300
+4% +$142K 0.36% 94
2015
Q1 		$3.81M Sell
160,620
-420
-0.3% -$9.42K 0.33% 96
2014
Q4 		$3.42M Buy
161,040
+12,780
+9% +$257K 0.33% 94
2014
Q3 		$2.52M Sell
148,260
-13,860
-9% -$219K 0.26% 122
2014
Q2 		$2.32M Buy
+162,120
New +$2.2M 0.23% 135

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Twin Capital Management's EW Position: Q1 2026 in Review

Twin Capital Management reduced its Edwards Lifesciences (EW) stake by 1.6% in Q1 2026, selling an estimated $11.6K and leaving 8,486 shares worth $680K. The position accounts for 0.09% of the portfolio, ranked #216.

Twin Capital Management first reported a position in EW in Q2 2014 and has held it in 45 quarters since. The position peaked at $7.62M in Q3 2016. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Twin Capital Management held 8,486 shares of Edwards Lifesciences worth $680K as of Q1 2026.
  • Twin Capital Management sold 141 Edwards Lifesciences shares in Q1 2026, an estimated $11.6K.
  • Edwards Lifesciences made up 0.09% of Twin Capital Management's portfolio in Q1 2026, its #216 holding.
  • Twin Capital Management first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 45 quarters since.
  • Twin Capital Management's Edwards Lifesciences position peaked at $7.62M in Q3 2016.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.